Medicinal chemistry support to ncats APP medchem initiative
Active Awarded Last action
- Contract number
- 75N91022F00025
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,260,028
Award facts
- Contract value 100% obligated
- $6,260,028.00 Current and potential, with all options
- Completion date 81% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21703, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$340,177 | |
| Supplemental Agreement for work within scope | $194,206 | |
| Original award | $6,405,999 |
About this award
The National Cancer Institute (NCI) awarded a $6.26M delivery order contract to Leidos Biomedical Research Inc. for medicinal chemistry support to the National Center for Advancing Translational Sciences (NCATS) App MedChem Initiative. This cost-plus-fixed-fee delivery order, awarded on September 28, 2022, with an ultimate completion date of September 27, 2027, does not utilize a set-aside designation. The work will be performed in Frederick, Maryland, where Leidos operates as a Federally Funded Research and Development Center (FFRDC) contractor. Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc., a global technology and engineering solutions provider based in Reston, Virginia, that maintains significant biomedical research capabilities across federal agencies.
This contract supports the NCATS medicinal chemistry initiative, aligning with the National Institutes of Health's mission to accelerate translational research and drug discovery processes. Leidos Biomedical Research Inc. will provide comprehensive medicinal chemistry expertise and support services, leveraging its established capabilities in biomedical research, scientific analysis, and advanced technological solutions. The company's extensive experience managing cost-plus-fixed-fee delivery orders for NCI and related agencies, combined with its FFRDC status, positions it to deliver critical research and development support for this multi-year initiative focused on advancing chemical science and therapeutic development.
Quick answers
Who was awarded contract 75N91022F00025?
75N91022F00025 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 28, 2022.
How much is contract 75N91022F00025 worth?
The government has obligated $6,260,028 on 75N91022F00025.
Is contract 75N91022F00025 an order under another contract?
Yes. 75N91022F00025 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00025 competed?
The extent of competition for 75N91022F00025 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award